Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$35.03 USD

35.03
70,626

-0.38 (-1.07%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $35.07 +0.04 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Merit Medical (MMSI) to Acquire Cianna Medical, Shares Up

by Zacks Equity Research

Merit Medical (MMSI) to leverage on Cianna Medical's SAVI and SCOUT platforms. The company plans to retain Cianna Medical's commercial and R&D teams after closure of the transaction.

    Zacks Equity Research

    Omeros (OMER) Surges: Stock Moves 10.2% Higher

    by Zacks Equity Research

    Omeros (OMER) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

      Zacks Equity Research

      Baxter Collaborates With Mayo Clinic to Open Renal Care Center

      by Zacks Equity Research

      Per the agreement, Baxter (BAX) and Mayo Clinic researchers to form an outpatient clinic for kidney disease management, home dialysis and in-center dialysis services.

        Zacks Equity Research

        Surmodics Sees Hammer Chart Pattern: Time to Buy?

        by Zacks Equity Research

        Surmodics has been struggling lately, but the selling pressure may be coming to an end soon.

          Zacks Equity Research

          Is Surmodics (SRDX) Outperforming Other Medical Stocks This Year?

          by Zacks Equity Research

          Is (SRDX) Outperforming Other Medical Stocks This Year?

            Zacks Equity Research

            Intuitive Surgical and InTouch Collaborate for IoMT Services

            by Zacks Equity Research

            Intuitive Surgical's (ISRG) IoMT likely to benefit patients; market prospects impressive.

              Sreyoshi Mukherjee headshot

              3 Top Stocks From the Booming US Medical Products Industry

              by Sreyoshi Mukherjee

              The U.S. Medical Products industry is sturdy on solid focus on technological advancement.

                Zacks Equity Research

                GW Pharmaceuticals (GWPH) Catches Eye: Stock Jumps 5.9%

                by Zacks Equity Research

                GW Pharmaceuticals (GWPH) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

                  Zacks Equity Research

                  Medical - Products Stock Outlook: Short-Term Pain Inevitable

                  by Zacks Equity Research

                  Near-term growth prospects of medical products are being questioned due to trade war apprehensions and President Trump's imposition of fresh tariffs on about $200 billion on Chinese imports.

                    Zacks Equity Research

                    Here's Why You Should Invest in Surmodics (SRDX) Stock Now

                    by Zacks Equity Research

                    Continuous focus on R&D and a raised guidance for fiscal 2018 make Surmodics (SRDX) a lucrative pick for investors.

                      Zacks Equity Research

                      Baxter's Actifuse Flow Bone Graft Substitute Gets FDA Nod

                      by Zacks Equity Research

                      The latest FDA approval for Baxter's (BAX) Actifuse Flow bone graft is likely to boost its Advanced Surgery segment.

                        Zacks Equity Research

                        Why Is SurModics (SRDX) Up 19.9% Since Last Earnings Report?

                        by Zacks Equity Research

                        SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                          Zacks Equity Research

                          Zacks.com highlights: Buckle, Illumina, Surmodics and Huntington Ingalls Industries

                          by Zacks Equity Research

                          Zacks.com highlights: Buckle, Illumina, Surmodics and Huntington Ingalls Industries

                            Tirthankar Chakraborty headshot

                            4 of the Best Efficient Stocks to Enrich Your Portfolio

                            by Tirthankar Chakraborty

                            A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

                              Zacks Equity Research

                              Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International

                              by Zacks Equity Research

                              Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International

                                Tirthankar Chakraborty headshot

                                4 Winning Stocks With Solid Efficiency Level

                                by Tirthankar Chakraborty

                                A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

                                  Zacks Equity Research

                                  Surmodics' (SRDX) IVD Unit Boosts Growth, R&D Focus Solid

                                  by Zacks Equity Research

                                  Surmodics' (SRDX) strong focus on R&D to provide it a competitive edge in the MedTech space.

                                    Zacks Equity Research

                                    Surmodics (SRDX) Beats Q3 Earnings Estimates, Raises '18 View

                                    by Zacks Equity Research

                                    Surmodics' (SRDX) third-quarter fiscal 2018 results benefit from increase in royalty and license fee revenues.

                                      Zacks Equity Research

                                      SurModics (SRDX) Tops Q3 Earnings and Revenue Estimates

                                      by Zacks Equity Research

                                      SurModics (SRDX) delivered earnings and revenue surprises of 437.50% and 12.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                                        Sweta Killa headshot

                                        5 Top Performing Stocks of the Best ETF of 1H2018

                                        by Sweta Killa

                                        Inside the top performing stocks of the top ETF of the first half of 2018.

                                          Zacks Equity Research

                                          Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips

                                          by Zacks Equity Research

                                          Zacks.com featured highlights include: Illumina, Lululemon, Surmodics and ConocoPhillips

                                            Tirthankar Chakraborty headshot

                                            4 of the Best Efficient Stocks to Buy for Superb Returns

                                            by Tirthankar Chakraborty

                                            We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

                                              Zacks Equity Research

                                              Here's Why You Must Add Surmodics (SRDX) to Your Portfolio

                                              by Zacks Equity Research

                                              Surmodics' (SRDX) efforts to improve research and development stature bode well.

                                                Zacks Equity Research

                                                SYK or SRDX: Which is a Better Medical Product Stock?

                                                by Zacks Equity Research

                                                Stryker (SYK) and Surmodics' (SRDX) strong fundamentals and rising share price make them close contenders.

                                                  Zacks Equity Research

                                                  Baxter (BAX) Soars to a 52-Week High, Time to Cash Out?

                                                  by Zacks Equity Research

                                                  Baxter International Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for BAX for clues.